…
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Spencer Pharmaceutical Inc (OTC: SPPH) is a small publicly traded company identified in the pharmaceutical sector; public disclosures and filings are sparse. Long-term growth may depend on product development, licensing or commercialization and access to financing, so investors may find upside exposure to early-stage pharmaceutical assets but face high information uncertainty.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Income before tax | -0.94M | -0.94M | 0.44M |
| Minority interest | 0.00M | 0.00M | 0.00M |
| Net income | -0.94M | 0.00M | 0.44M |
| Selling general administrative | 0.94M | 0.94M | 0.94M |
| Gross profit | 0.00M | 0.00M | 0.44M |
| Ebit | -0.94M | 0.00M | 0.44M |
| Non operating income net other | 0.00M | 0.00M | 0.00M |
| Operating income | -0.94M | -0.94M | 0.44M |
| Other operating expenses | 0.00M | 0.00M | 0.00M |
| Interest expense | 0.00M | 0.00M | 0.00M |
| Extraordinary items | 0.00M | 0.00M | 0.00M |
| Non recurring | 0.00M | 0.00M | 0.00M |
| Other items | 0.00M | 0.00M | 0.00M |
| Income tax expense | 0.00M | 0.00M | 0.00M |
| Total revenue | 0.00M | 0.00M | 0.44M |
| Total operating expenses | 0.94M | 0.00M | 0.00M |
| Cost of revenue | 0.00M | 0.00M | 0.00M |
| Total other income expense net | 0.00M | 0.00M | 0.00M |
| Discontinued operations | 0.00M | 0.00M | 0.00M |
| Net income from continuing ops | -0.94M | -0.94M | 0.44M |
| Net income applicable to common shares | -0.94M | -0.94M | 0.44M |
| Preferred stock and other adjustments | 0.00M | 0.00M | 0.00M |
| Breakdown | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Total assets | 0.77M | 0.06M | 0.00M |
| Intangible assets | 0.32M | 0.06M | 0.00M |
| Other current assets | 0.00M | 0.00M | 0.00M |
| Total liab | 1.64M | 0.06M | 0.00M |
| Total stockholder equity | -0.87M | 0.00M | 0.00M |
| Deferred long term liab | 0.00M | 0.00M | 0.00M |
| Other current liab | 0.00M | 0.00M | 0.00M |
| Common stock | 0.27M | 0.20M | 0.01M |
| Retained earnings | -18.00M | -17.05M | -17.05M |
| Other liab | 0.00M | 0.00M | 0.00M |
| Good will | 0.00M | 0.00M | 0.00M |
| Other assets | 0.00M | 0.00M | 0.00M |
| Cash | 0.46M | 0.00M | 0.00M |
| Total current liabilities | 1.64M | 0.06M | 0.00M |
| Short term debt | 0.00M | 0.00M | 0.00M |
| Short long term debt | 2.91M | 0.09M | 0.00M |
| Other stockholder equity | -0.09M | -0.10M | 2.46M |
| Property plant equipment | 0.00M | 0.00M | 0.00M |
| Total current assets | 0.46M | 0.00M | 0.00M |
| Long term investments | 0.00M | 0.00M | 0.00M |
| Net tangible assets | -1.19M | -0.06M | 0.00M |
| Short term investments | 0.00M | 0.00M | 0.00M |
| Long term debt | 0.00M | 0.00M | 0.00M |
| Inventory | 0.00M | 0.00M | 0.00M |
| Accounts payable | 0.47M | 0.00M | 0.00M |
| Total permanent equity | 0.00M | 0.00M | 0.00M |
| Noncontrolling interest in consolidated entity | 0.00M | 0.00M | 0.00M |
| Temporary equity redeemable noncontrolling interests | 0.00M | 0.00M | 0.00M |
| Accumulated other comprehensive income | 0.00M | 0.00M | 0.00M |
| Additional paid in capital | 0.00M | 0.00M | 0.00M |
| Common stock total equity | 0.00M | 0.00M | 0.00M |
| Preferred stock total equity | 0.00M | 0.00M | 0.00M |
| Retained earnings total equity | 0.00M | 0.00M | 0.00M |
| Treasury stock | 0.00M | 0.00M | 0.00M |
| Accumulated amortization | 0.00M | 0.00M | 0.00M |
| Non currrent assets other | 0.00M | 0.00M | 0.00M |
| Deferred long term asset charges | 0.00M | 0.00M | 0.00M |
| Non current assets total | 0.00M | 0.00M | 0.00M |
| Capital lease obligations | 0.00M | 0.00M | 0.00M |
| Long term debt total | 0.00M | 0.00M | 0.00M |
| Breakdown | 2010-12-31 | 2009-12-31 | 2008-12-31 |
|---|---|---|---|
| Type | yearly | yearly | yearly |
| Date | 2010-12-31 | 2009-12-31 | 2008-12-31 |
| Investments | 0.00M | 0.00M | 0.00M |
| Change to liabilities | 0.00M | 0.00M | 0.00M |
| Total cashflows from investing activities | -0.26M | -0.06M | -0.06M |
| Net borrowings | 0.00M | 0.00M | 0.00M |
| Total cash from financing activities | 0.07M | 0.07M | 0.07M |
| Change to operating activities | 1.59M | 0.06M | -0.44M |
| Net income | -0.94M | 0.00M | 0.44M |
| Change in cash | 0.46M | 0.46M | -0.00M |
| Total cash from operating activities | 0.64M | 0.06M | -0.00M |
| Depreciation | 0.00M | 0.00M | 0.00M |
| Other cashflows from investing activities | 0.00M | 0.00M | 0.00M |
| Dividends paid | 0.00M | 0.00M | 0.00M |
| Change to inventory | 0.00M | 0.00M | 0.00M |
| Change to account receivables | 0.00M | 0.00M | 0.00M |
| Sale purchase of stock | 0.17M | 4.08M | 0.66M |
| Other cashflows from financing activities | 0.00M | -2.55M | -2.55M |
| Change to netincome | 0.00M | 0.00M | 0.00M |
| Capital expenditures | 0.00M | 0.00M | 0.00M |
| Change receivables | 0.00M | 0.00M | 0.00M |
| Cash flows other operating | 0.00M | 0.00M | 0.00M |
| Exchange rate changes | 0.00M | 0.00M | 0.00M |
| Cash and cash equivalents changes | 0.00M | 0.00M | 0.00M |
|
Stock Name
|
Change
(USD) |
Price
(USD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| SPPH Spencer Pharmaceutical Inc |
- -% |
0.00 | - | - | - | - |
| DOGEF Orsted A/S |
- -% |
20.13 | 28.82 | 0.66 | 6.50 | 0.07 |
| TBB AT&T Inc. 5.35% GLB NTS 66 |
0.12 0.70% |
17.72 | 4.60 | - | - | - |
| CCZ Comcast Holdings Corp |
- -% |
62.32 | 55.07 | - | - | - |
| STMZF Scottish Mortgage Investment Trust PLC |
-1.09 5.69% |
18.00 | - | - | 2.56 | - |
Spencer Pharmaceutical Inc. develops drug platform technologies for the treatment of neurological deceases. The company specializes in the controlled release of existing therapeutic molecules in the areas of central nervous system, which include Alzheimer and Parkinson diseases, and brain cancer; and patented slow release drug delivery technology for the treatment of type-2 diabetes, arthritis, and other potential applications. It has operations primarily in North America and Europe. The company was incorporated in 1998 and is based in Boston, Massachusetts.
8 Faneuil Hall Marketplace, Boston, MA, United States, 02109
617-973-5017
| Name | Title | Year Born |
|---|---|---|
| Dr. Maximilien Arella | Chairman, Chief Exec. Officer and Pres | 1956 |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.